{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:36Z","timestamp":1776988776249,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T00:00:00Z","timestamp":1359158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T00:00:00Z","timestamp":1359158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10637-013-9931-1","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T12:21:17Z","timestamp":1359116477000},"page":"1008-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium"],"prefix":"10.1007","volume":"31","author":[{"given":"Srikala S.","family":"Sridhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien J.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Som D.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian F.","family":"Tannock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoom A.","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Halford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,26]]},"reference":[{"issue":"4","key":"9931_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","volume":"30","author":"NK Janzen","year":"2003","unstructured":"Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 30(4):843\u2013852","journal-title":"Urol Clin N Am"},{"issue":"9","key":"9931_CR2","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1002\/cncr.23851","volume":"113","author":"AS Belldegrun","year":"2008","unstructured":"Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ (2008) Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989\u20132005): a benchmark for emerging targeted cancer therapies. Cancer 113(9):2457\u20132463. doi:10.1002\/cncr.23851","journal-title":"Cancer"},{"issue":"Suppl 10","key":"9931_CR3","doi-asserted-by":"publisher","first-page":"x25","DOI":"10.1093\/annonc\/mdm411","volume":"18","author":"S Oudard","year":"2007","unstructured":"Oudard S, George D, Medioni J, Motzer R (2007) Treatment options in renal cell carcinoma: past, present and future. Ann Oncol Off J Eur Soc Med Oncol \/ ESMO 18(Suppl 10):x25\u2013x31. doi:10.1093\/annonc\/mdm411","journal-title":"Ann Oncol Off J Eur Soc Med Oncol \/ ESMO"},{"issue":"10","key":"9931_CR4","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","volume":"108","author":"C Coppin","year":"2011","unstructured":"Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 108(10):1556\u20131563. doi:10.1111\/j.1464-410X.2011.10629.x","journal-title":"BJU Int"},{"issue":"10","key":"9931_CR5","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","volume":"65","author":"SR Wedge","year":"2005","unstructured":"Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65(10):4389\u20134400. doi:10.1158\/0008-5472.CAN-04-4409","journal-title":"Cancer Res"},{"issue":"21","key":"9931_CR6","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","volume":"25","author":"J Drevs","year":"2007","unstructured":"Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 25(21):3045\u20133054. doi:10.1200\/JCO.2006.07.2066","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"9931_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00280-009-0979-8","volume":"64","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E (2009) Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 64(6):1165\u20131172. doi:10.1007\/s00280-009-0979-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"9931_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mrm.1910170208","volume":"17","author":"PS Tofts","year":"1991","unstructured":"Tofts PS, Kermode AG (1991) Measurement of the blood\u2013brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med Off J Soc Magn Reson Med \/ Soc Magn Reson Med 17(2):357\u2013367","journal-title":"Magn Reson Med Off J Soc Magn Reson Med \/ Soc Magn Reson Med"},{"issue":"1","key":"9931_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"issue":"2","key":"9931_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. doi:10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"issue":"2","key":"9931_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Group TS (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134. doi:10.1056\/NEJMoa060655","journal-title":"N Engl J Med"},{"issue":"13","key":"9931_CR12","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol Off J Am Soc Clin Oncol 28(13):2144\u20132150. doi:10.1200\/JCO.2009.26.7849","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"9931_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 28(6):1061\u20131068. doi:10.1200\/JCO.2009.23.9764","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"9931_CR14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281. doi:10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"issue":"9637","key":"9931_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. doi:10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"12","key":"9931_CR16","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298\u20132308. doi:10.1158\/1535-7163.MCT-11-0264","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"9931_CR17","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465. doi:10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"issue":"2","key":"9931_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.eururo.2011.10.032","volume":"61","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG (2012) Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61(2):307\u2013316. doi:10.1016\/j.eururo.2011.10.032","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"9931_CR19","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3747\/co.v18is2.958","volume":"18","author":"SJ Hotte","year":"2011","unstructured":"Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F (2011) Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr Oncol 18(Suppl 2):S11\u2013S19","journal-title":"Curr Oncol"},{"issue":"7","key":"9931_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ejca.2012.02.048","volume":"48","author":"C Seidel","year":"2012","unstructured":"Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, Grunwald V (2012) Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer 48(7):1023\u20131030. doi:10.1016\/j.ejca.2012.02.048","journal-title":"Eur J Cancer"},{"issue":"9","key":"9931_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763\u2013773. doi:10.1093\/jnci\/djr128","journal-title":"J Natl Cancer Inst"},{"key":"#cr-split#-9931_CR22.1","doi-asserted-by":"crossref","unstructured":"Rini BI, Grunwald V, Fishman MN, Melichar B, Ueda T, Karlov PA, Bair AH, Chen Y, Kim S, Jonasch E (2012) Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 30, 2012 (suppl","DOI":"10.1200\/jco.2012.30.15_suppl.4503"},{"key":"#cr-split#-9931_CR22.2","doi-asserted-by":"crossref","unstructured":"Rini BI, Grunwald V, Fishman MN, Melichar B, Ueda T, Karlov PA, Bair AH, Chen Y, Kim S, Jonasch E (2012) Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic","DOI":"10.1200\/jco.2012.30.15_suppl.4503"},{"key":"#cr-split#-9931_CR22.3","doi-asserted-by":"crossref","unstructured":"(PK) analyses from a randomized phase II study. J Clin Oncol 30, 2012 (suppl; abstr 4503)","DOI":"10.1200\/jco.2012.30.15_suppl.4503"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9931-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9931-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:36:39Z","timestamp":1678509399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,26]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9931"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9931-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,26]]},"assertion":[{"value":"5 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}